RYR2 and catecholaminergic polymorphic ventricular tachycardia: Some studies have shown that carvedilol suppresses RyR2-mediated calcium waves and prevents calcium release-induced triggered ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) or heart failure (HF) [14,15].